Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Next Previous
Trial Profile

Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tretinoin (Primary) ; Cytarabine; Etoposide; Idarubicin; Pegfilgrastim
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Feb 2021 Results (n=75) of RATIFY, AMLSG 16-10, AMLSG 07-04 and AMLSG 11-08 trials assessing clonal evolution of FLT3-ITD positive AML in patients with relapsed and refractory disease who were treated with intensive chemotherapy in combination with the multi-kinase inhibitor midostaurin, published in the Blood.
    • 06 Dec 2016 Results of analysis comparing condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim using data from this trial presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results assessing minimal residual disease monitoring in Acute Myeloid Leukemia study group (AML HD93, NCT00146120, NCT00151255, NCT00151242, NCT00850382 and NCT02013648 trials) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top